Novavax Announces Progress on Sanofi Agreement

About this update from Novavax, Inc.

[{"type":"text","content":"\n GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adjuvant. The companies have amended their CLA to expand Sanofi's license to include use of Novavax's Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program. Sanofi recently received funding from the Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response, part of the U.S. Department of Health and Human Services, for early-stage work on this vaccine candidate including the Matrix-M adjuvant under Contract 75A50122D00003.\n The CLA amendment enables Sanofi's use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate(s) through Phase 2. If Sanofi enters Phase 3 clinical development, the parties will negotiate license rates and financial terms.\n \"We're excited that Sanofi has recognized the potential of a pandemic influenza vaccine candidate that contains Novavax's validated Matrix-M® adjuvant,\" said John C. Jacobs, President and Chief Executive Officer, Novavax. \"We're pleased to deepen our partnership with leading vaccine innovator, Sanofi, and to share our technology in support of U.S. pandemic preparedness efforts with the goal of potentially saving millions of lives.\"\n The amendment broadens the partnership between Novavax and Sanofi and adds to the terms of the original agreement that specifies that Novavax is eligible to receive up to $200 million for the first four products created by Sanofi utilizing its Matrix-M adjuvant, and up to $210 million in milestone payments for each product including Matrix-M thereafter, plus ongoing royalties for all Sanofi products utilizing Matrix-M. Sanofi is currently exploring additional opportunities with Matrix-M.\n \n About Matrix-M® AdjuvantMatrix-M is Novavax's proprietary adjuvant that can be added to a vaccine to stimulate a stronger immune response and is currently used in globally approved vaccines. It is clinically proven to induce potent, durable and broad immune responses with an acceptable safety and tolerability profile.1 The Company's recombinant, protein-based nanoparticles are combined with its Matrix-M adjuvant, constituting the basis of Novavax's expanding...

More updates from Novavax, Inc.